Abstract:Objective: To test whether cerebrospinal fluid (CSF) α-synuclein is altered in Alzheimer’s disease (AD) and different AD pathophysiological profiles based on “ATN” classifications and whether it associated with other AD biomarkers, cognitive decline and imaging evidence of neurodegeneration. Background: More than 50% sporadic AD patients exhibit accumulation of α-synuclein in their brains. CSF α-synuclein could be a potential biomarker of AD. Design/Methods: This prospective case-control study included 385 subjects: 109 cognitively healthy controls, 117 patients with stable mild cognitive impairment (sMCI), 68 patients with progressive mild cognitive impairment (pMCI) and 91 patients with AD dementia from the Alzheimer’s disease Neuroimaging Initiative. The study dates were September 2005, to December 2011. Associations were investigated between CSF α-synuclein and diagnosis, Aβ/tau pathologic features, cognition, brain structure and metabolism. Results: CSF α-synuclein concentration was significantly higher in the AD and pMCI groups compared with the cognitively normal group (P Conclusions: CSF α-synuclein is associated with AD diagnosis and with CSF tau levels, cognition and imaging evidence of neurodegeneration of the disease. This finding implies usefulness for CSF α-synuclein as a potential biomarker for AD. Study Supported by: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI)(National Institutes of Health Grant U01 AG024904) and DOD ADNI(Department of Defense award number W81XWH-12-2-0012). ADNIis funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Euro Immun; and F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare;; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research u0026 Development, LLC.; Johnson u0026 Johnson Pharmaceutical Research u0026 Development LLC.; Medpace, Inc.; MerckC Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California Disclosure: Dr. Li has nothing to disclose. Dr. Yu has nothing to disclose. Dr. Tan has nothing to disclose.

The Cerebrospinal Fluid Free-Glycans Hex1 and HexNAc1Hex1Neu5Ac1 as Potential Biomarkers of Alzheimer's Disease

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment

In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease

Human Brain and Blood N-Glycome Profiling in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias

Peptide-Bound Glycative, AGE and Oxidative Modifications as Biomarkers for the Diagnosis of Alzheimer's Disease—A Feasibility Study

What Can N-glycomics and N-glycoproteomics of Cerebrospinal Fluid Tell Us about Alzheimer Disease?

Cerebrospinal fluid α-synuclein as a potential biomarker for Alzheimer’s disease (P4.174)

Distinct patterns of plaque and microglia glycosylation in Alzheimer's disease

[Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer's Dementia]

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

Biomarkers for Alzheimer's disease: current status and prospects for the future

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease

Human brain glycoform coregulation network and glycan modification alterations in Alzheimer's disease

Current state of Alzheimer’s fluid biomarkers

Can Small Molecules Provide Clues on Disease Progression in Cerebrospinal Fluid from Mild Cognitive Impairment and Alzheimer’s Disease Patients?

Multilayered N-Glycoproteome Profiling Reveals Highly Heterogeneous and Dysregulated Protein N-Glycosylation Related to Alzheimer’s Disease

Fc N‐glycosylation of autoreactive Aβ antibodies as a blood‐based biomarker for Alzheimer's disease

Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Targeted proteomic profiling in cerebrospinal fluid and plasma identifies biomarkers for Alzheimer’s disease